RE:RE:Feb 27 mtglscfa wrote: Gagnon better pre-announce q4 results ahead of the meeting (if they are good) to get some votes
I don't know how the events line up for the Feb. 27 meeting; but in an ideal world lots would happen to clarify the situation.
1) In the least it would be nice to announce that CZO's major client has begun reordering and that the new powder formulations of beta glucan and avenanthramide have been launched with Symrise. Powder beta glucan was to be launched "very, very soon" according to Gilles October presentation opening up new markets. How has the launch of
macimorelin gone in Europe, etc.? 2) With cost savings due to the AEZS/CZO merger, CZO's major client having potentially commenced reordering, the potential launch of powder beta glucan, and revenue ramping from the launch of macimorelin in Europe what is the burn rate and how long before cash runs out?
3) AEZS's pediatric diagnostic test trial was to be fully enrolled by December 31, 2023. Will they have trial results by the time of the Feb. 27, 2024 meeting and does North American relicensing happen upon full de-risking(FDA approval) or by the time of the Feb. 27 meeting with potential clinical data? Do they plan on selling this asset as non-core and turning it into a PGX plant as PGX reaches 100L scale? A licensing deal could also be monitized for an upfront payment with milestones.
4) The 5X PGX scale-up is to be commissioned by the end of Q1 2024. Will it have successfully been commissioned by the Feb. 27 meeting on time and on budget? Is it performing equal to or better than expectations? 50% of the equipment and infrastructure was believed in place for the 10X PGX scale-up as of the November 7, 2023 news release. Where does Natex believe they are now and is it on time and on budget for expected commissioning in Q4 2024? Is this the trigger for a potential PGX deal?
5) Nov 29, 2023 news release: "
Protocol designed for a head-to-head study in animals for testing immune properties of PGX-YBG against a commercial formulation." Has this study been completed potentially confirming a 5X increase in immune stimulation for PGX-YBG. This could further strengthen the belief that PGX-YBG is the emerging gold standard in the immune booster category as PGX is being scaled.
6) Will the single ascending dose portion of the avenanthramide clinical trial have been completed at doses from 30mg to 960mg establishing a potentially strong safety/tolerability profile?
7) Does AEZS have a 'go' decision for a clinical trial for one of its pipeline drugs(eg. AIM Biologicals)?
8) Will the wound healing program have its data from the ongoing studies with the Angiogenesis Foundation? It had already completed testing in the animal model others use to advance to human testing with Gilles calling it a 'home run'. July, 2023 news release: "...additional expected evidence-based results from this study will not only reinforce and/or add claims to existing cosmetics formulations but should further position Ceapro in dermatology along with a pharmaceutical and medical supplies partner who will benefit from additional selling points arising from this unique research program."
9) A plan with the path to commercial revenue and spending required to get there as well as the priorities.